The main purpose of this legislation, known as the "Preserving Life-saving Access to Specialty Medicines in America Act" or the "PLASMA Act," is to ensure that patients have continued access to plasma-derived products, which are important medications made from human blood or plasma. The law aims to gradually introduce a discount program for these products under Medicare, specifically for those who need them and may face high costs. Key provisions of the law include a phased-in discount structure for plasma-derived products starting in 2026.